HR 2113 — Prescription Drug STAR Act

2113 IntroducedReported in House (IH)](RH)] <DOC> 116thUnion CONGRESSCalendar 1stNo. Session H.

571 116th CONGRESS 2d Session H.

2113 To[Report amendNo. titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes.

116-688, Part I] To amend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes.

which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________December A24, BILL2020 ToAdditional amendsponsors: titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes.

Mr.

Van Drew, Ms.

Finkenauer, Ms.

Houlahan, Mr.

Raskin, Mr.

McAdams, Ms.

Underwood, Ms.

Slotkin, Mr.

Lipinski, Ms.

Lofgren, and Mr.

Amodei December 24, 2020 Reported from the Committee on Ways and Means with an amendment [Strike out all after the enacting clause and insert the part printed in italic] December 24, 2020 Committee on Energy and Commerce discharged;

committed to the Committee of the Whole House on the State of the Union and ordered to be printed [For text of introduced bill, see copy of bill as introduced on April 8, 2019] _______________________________________________________________________ A BILL To amend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes.

If the Secretary determines, with respect to a year, there is such an increase with respect to an applicable drug, the manufacturer of the applicable drug shall submit to the Secretary the justification described in subsection (c), subject to subsection (b)(4), for each such triggered SPIKE increase in accordance with the timing described in subsection (d).(d)).

and ``(B) the number of applicable drugs for which a triggered SPIKE increase would occur for such year ofif such an alternative percentage, dollar amount, or period were applied for such year.

``Each manufacturer (within the meaning of section 1128L of the Social Security Act) shall file a return (as(at such time and in such form and manner as the Secretary may provide) showing for eachsuch year with respect to which such section applies all information and supporting documentation and the certification included within a justification reported by the manufacturer under subsection (c)(1) of such section.''.

``Each applicable manufacturer (within the meaning of section 1128G(a)(3) of the Social Security Act) shall file a return (as(at such time and in such form and manner as the Secretary may provide) showing for eachsuch year to which such section applies-- ``(1) the amount described in section 1128G(a)(3)(A)(ii) of such Act with respect to such year, and ``(2) the portion of such amount for which a deduction was claimed under section 162.''.

``(e) Public Availability of Certain Information.-- ``(1) In general.--In order to allow the comparison of PBMs' ability to negotiate rebates, discounts, and price concessions and the amount of such rebates, discounts, and price concessions that are passed through to plan sponsors, beginning January 1, 2020, the Secretary shall make available on the Internet website of the Department of Health and Human Services the information with respect to the second preceding calendar year provided to the Secretary on generic dispensing rates (as described in paragraph (1) of subsection (b))(b) and information provided to the Secretary under paragraphs (2) and (3) of such subsection that, as determined by the Secretary, is with respect to each PBM.

<all>Union Calendar No.

571 116th CONGRESS 2d Session H.

R.

2113 [Report No.

116-688, Part I] _______________________________________________________________________ A BILL To amend titles XI and XVIII of the Social Security Act to provide for drug manufacturer price transparency, to require certain manufacturers to report on product samples provided to certain health care providers, and for other purposes.

_______________________________________________________________________ December 24, 2020 Reported from the Committee on Ways and Means with an amendment December 24, 2020 Committee on Energy and Commerce discharged;

committed to the Committee of the Whole House on the State of the Union and ordered to be printed